Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Liabilities: 2024-2025

Historic Other Non-Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 1 years, with Mar 2025 value amounting to $3.8 million.

  • Corvus Pharmaceuticals' Other Non-Current Liabilities was N/A to $3.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.8 million, marking a year-over-year change of. This contributed to the annual value of $28.9 million for FY2024, which is N/A change from last year.
  • Corvus Pharmaceuticals' Other Non-Current Liabilities amounted to $3.8 million in Q1 2025, which was down 86.86% from $28.9 million recorded in Q4 2024.
  • In the past 5 years, Corvus Pharmaceuticals' Other Non-Current Liabilities registered a high of $40.0 million during Q3 2024, and its lowest value of $3.8 million during Q1 2025.
  • Over the past 2 years, Corvus Pharmaceuticals' median Other Non-Current Liabilities value was $18.0 million (recorded in 2024), while the average stood at $20.0 million.